David R. Bauer

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $207 million public offering of common stock of Denali Therapeutics,…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 3,152,712 shares of common stock of Applied Therapeutics, Inc., including 411,223 shares of common…

Davis Polk advised the underwriters on the SEC-registered initial public offering by I-Mab of 7,407,400 American depositary shares, each 10 ADSs representing 23 ordinary shares, for total…

Davis Polk is advising Charles River Laboratories International, Inc. on its approximately $380 million acquisition of HemaCare Corporation. The proposed purchase price equates to $25.40…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $195.6 million public offering of common stock of Forty Seven, …

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $224.3 million offering of common stock of Constellation…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the $25 million public offering of 4,166,667 common shares of…

Davis Polk advised the initial purchasers in connection with an unregistered offering by AbbVie Inc. of $30 billion aggregate principal amount of senior notes, consisting of (i) $750…

Davis Polk is advising Roche on its acquisition of Promedior, Inc. Under the terms of the merger agreement, Roche will make an upfront cash payment of $390 million, plus additional…

Davis Polk advised Shockwave Medical, Inc. on its SEC-registered public offering of 2,481,781 shares of common stock for an aggregate price to the public of approximately $90 million. The…